HealthEquity, Inc. (NASDAQ:HQY) Given Average Rating of “Buy” by Analysts

Shares of HealthEquity, Inc. (NASDAQ:HQY) have been assigned an average recommendation of “Buy” from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. Eleven research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $96.17.

A number of brokerages have recently commented on HQY. Barrington Research reiterated an “outperform” rating and set a $100.00 price objective on shares of HealthEquity in a research report on Friday, March 22nd. JMP Securities began coverage on HealthEquity in a research report on Thursday, April 4th. They set a “mkt outperform” rating and a $101.00 price objective for the company. Royal Bank of Canada increased their price objective on HealthEquity from $90.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, March 20th. KeyCorp increased their price objective on HealthEquity from $85.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, March 22nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a research note on Tuesday, April 2nd.

HealthEquity Stock Performance

HQY opened at $79.27 on Friday. The company has a market capitalization of $6.90 billion, a price-to-earnings ratio of 123.86, a price-to-earnings-growth ratio of 1.16 and a beta of 0.55. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.76 and a quick ratio of 4.76. HealthEquity has a 1-year low of $54.09 and a 1-year high of $84.49. The business has a 50 day moving average price of $79.77 and a two-hundred day moving average price of $75.41.

HealthEquity (NASDAQ:HQY) last released its earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.08. The firm had revenue of $262.39 million during the quarter, compared to the consensus estimate of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. Research analysts predict that HealthEquity will post 2.12 EPS for the current fiscal year.

Insider Activity

In other news, EVP Delano Ladd sold 2,558 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $82.59, for a total value of $211,265.22. Following the sale, the executive vice president now directly owns 47,438 shares of the company’s stock, valued at $3,917,904.42. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Delano Ladd sold 2,558 shares of HealthEquity stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $82.59, for a total transaction of $211,265.22. Following the sale, the executive vice president now directly owns 47,438 shares of the company’s stock, valued at $3,917,904.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Evelyn S. Dilsaver sold 32,500 shares of HealthEquity stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total value of $2,576,925.00. Following the sale, the director now directly owns 32,123 shares in the company, valued at $2,547,032.67. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 68,823 shares of company stock valued at $5,482,975. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On HealthEquity

A number of institutional investors have recently added to or reduced their stakes in HQY. Vanguard Group Inc. boosted its holdings in HealthEquity by 1.7% during the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after purchasing an additional 149,133 shares in the last quarter. Wasatch Advisors LP boosted its holdings in HealthEquity by 8.3% during the first quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock valued at $604,803,000 after purchasing an additional 569,249 shares in the last quarter. FMR LLC boosted its holdings in HealthEquity by 19.1% during the third quarter. FMR LLC now owns 5,648,992 shares of the company’s stock valued at $412,659,000 after purchasing an additional 907,743 shares in the last quarter. Motley Fool Asset Management LLC boosted its holdings in HealthEquity by 3,001.0% during the first quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock valued at $307,097,000 after purchasing an additional 3,640,748 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in HealthEquity by 6.9% during the fourth quarter. Clearbridge Investments LLC now owns 2,357,572 shares of the company’s stock valued at $156,307,000 after purchasing an additional 152,897 shares in the last quarter. 99.55% of the stock is owned by institutional investors and hedge funds.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.